Batf3 Deficiency Reveals a Critical Role for CD8α + Dendritic Cells in Cytotoxic T Cell Immunity
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Although in vitro observations suggest that cross-presentation of antigens is mediated primarily by CD8alpha+ dendritic cells, in vivo analysis has been hampered by the lack of systems that selectively eliminate this cell lineage. We show that deletion of the transcription factor Batf3 ablated development of CD8alpha+ dendritic cells, allowing us to examine their role in immunity in vivo. Dendritic cells from Batf3-/- mice were defective in cross-presentation, and Batf3-/- mice lacked virus-specific CD8+ T cell responses to West Nile virus. Importantly, rejection of highly immunogenic syngeneic tumors was impaired in Batf3-/- mice. These results suggest an important role for CD8alpha+ dendritic cells and cross-presentation in responses to viruses and in tumor rejection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“appears essential for T cell-driven antitumor immunity (Hildner et al., 2008)”
From Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12 (2018) · cites this paper as Hildner et al., 2008
In the citing paper
“Both DC1s and DC2s expressed the DC markers Batf3, Flt3, H2-Dmb2 and Zbtb46 (Meredith et al., 2012; Hildner et al., 2008;); DC1 expressed Fscn1 and Ly 75 (DEC-205) whereas DC2s expressed CD209a (DC- SIGN), Mgl2 (CD301b) and Cd24a (Figure 2B and Figure S2B).”
From Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12 (2018) · cites this paper as Hildner et al., 2008
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Self-citationJung, S., Unutmaz, D., Wong, P., Sano, G.-I., De los Santos, K., Sparwasser, T., Wu, S., Vuthoori, S., Ko, K., Zavala, F., et al. (2002) · Immunity · doi:10.1016/s1074-7613(02)00365-5 · Cited by 1,773
Barnden, M. J., Allison, J., Heath, W. R., & Carbone, F. R. (1998) · Immunology & Cell Biology · doi:10.1046/j.1440-1711.1998.00709.x · Cited by 1,489
Differential Antigen Processing by Dendritic Cell Subsets in Vivo
Dudziak, D., Kamphorst, A. O., Heidkamp, G. F., Buchholz, V. R., Trumpfheller, C., Yamazaki, S., Cheong, C., Liu, K., Lee, H.-W., Park, C. G., et al. (2007) · Science · doi:10.1126/science.1136080 · Cited by 1,455
Cd8+ but Not Cd8− Dendritic Cells Cross-Prime Cytotoxic T Cells in Vivo
den Haan, J. M. M., Lehar, S. M., & Bevan, M. J. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.12.1685 · Cited by 1,328
Steady-state and inflammatory dendritic-cell development
Shortman, K., & Naik, S. H. (2007) · Nature Reviews Immunology · doi:10.1038/nri1996 · Cited by 1,190
Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens
Huang, A. Y. C., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., & Levitsky, H. (1994) · Science · doi:10.1126/science.7513904 · Cited by 1,160
Bevan, M. J. (1976) · The Journal of experimental medicine · doi:10.1084/jem.143.5.1283 · Cited by 956
Toll-like receptor 3 promotes cross-priming to virus-infected cells
Schulz, O., Diebold, S. S., Chen, M., Näslund, T. I., Nolte, M. A., Alexopoulou, L., Azuma, Y.-T., Flavell, R. A., Liljeström, P., & Reis e Sousa, C. (2005) · Nature · doi:10.1038/nature03326 · Cited by 921
A critical function for type I interferons in cancer immunoediting
Dunn, G. P., Bruce, A. T., Sheehan, K. C. F., Shankaran, V., Uppaluri, R., Bui, J. D., Diamond, M. S., Koebel, C. M., Arthur, C., White, J. M., et al. (2005) · Nature Immunology · doi:10.1038/ni1213 · Cited by 605
Cited by
Items 601–700 of 1,008
Langlois, R. A., Varble, A., Chua, M. A., García‐Sastre, A., & tenOever, B. R. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1206039109 · Cited by 73
Transcriptional control of dendritic cell development and functions
Amon, L., Lehmann, C. H. K., Barańska, A., Schoen, J., Heger, L., & Dudziak, D. (2019) · International review of cytology · doi:10.1016/bs.ircmb.2019.10.001 · Cited by 78
Hong, Y., Kim, Y. K., Kim, G. B., Nam, G., Kim, S. A., Park, Y., Yang, Y., & Kim, I. (2019) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2019.1670893 · Cited by 73
Caronni, N., Piperno, G. M., Simoncello, F., Romano, O., Vodret, S., Yanagihashi, Y., Dress, R. J., Dutertre, C., Bugatti, M., Bourdeley, P., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22535-z · Cited by 76
Lindsay, R. W. B., Darrah, P. A., Quinn, K. M., Wille-Reece, U., Mattei, L. M., Iwasaki, A., Kasturi, S. P., Pulendran, B., Gall, J. G. D., Spies, A., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000338 · Cited by 69
Connecting the Metabolic and Immune Responses to Cancer
Flint, T. R., Fearon, D. T., & Janowitz, T. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.03.001 · Cited by 73
Janela, B., Patel, A. A., Lau, M. C., Goh, C. C., Msallam, R., Kong, W. T., Fehlings, M., Hubert, S., Lum, J., Simoni, Y., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.001 · Cited by 78
Aligning bona fide dendritic cell populations across species
Dutertre, C., Wang, L., & Ginhoux, F. (2014) · Cellular Immunology · doi:10.1016/j.cellimm.2014.08.006 · Cited by 78
“[53] A. Bachem, E. Hartung, S. Guttler, A. Mora, X. Zhou, A. Hegemann, M. Plantinga, E. Mazzini, P. Stoitzner, S. Gurka, V. Henn, H.W. Mages, R.A. Kroczek, Expression of XCR1 characterizes the Batf3-dependent lineage of dendritic cells capable of antigen cross-presentation, Front.”
InfluentialYang, M., Li, G., Fan, L., Zhang, G., Xu, J., & Zhang, J. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.12.052 · Cited by 69
BDCA3+CLEC9A+ human dendritic cell function and development
van der Aa, E., van Montfoort, N., & Woltman, A. M. (2014) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2014.05.016 · Cited by 82
Fukaya, T., Murakami, R., Takagi, H., Sato, K., Sato, Y., Otsuka, H., Ohno, M., Hijikata, A., Ohara, O., Hikida, M., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1202208109 · Cited by 69
DCIR2+ cDC2 DCs and Zbtb32 Restore CD4+ T-Cell Tolerance and Inhibit Diabetes
Price, J. D., Hotta-Iwamura, C., Zhao, Y., Beauchamp, N. M., & Tarbell, K. V. (2015) · Diabetes · doi:10.2337/db14-1880 · Cited by 72
Beavis, P. A., Henderson, M. A., Giuffrida, L., Davenport, A. J., Petley, E. V., House, I. G., Lai, J., Sek, K., Milenkovski, N., John, L. B., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0291 · Cited by 68
“CD103 + DCs are highly efficient at tumor antigen presentation (26, 28, 48) and have been shown to enhance the therapeutic activity of anti–PDL-1/ BRAF inhibition (29) or anti-TIM3 (49).”
BackgroundConventional Dendritic Cells Impair Recovery after Myocardial Infarction
Lee, J. S., Jeong, S., Kim, S., Chalifour, L. E., Yun, T. J., Miah, M. A., Li, B., Majdoubi, A., Sabourin, A., Keler, T., et al. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1800322 · Cited by 76
Human intratumoral therapy: Linking drug properties and tumor transport of drugs in clinical trials
Huang, A., Pressnall, M. M., Lu, R., Huayamares, S. G., Griffin, J. D., Groer, C. E., DeKosky, B. J., Forrest, M. L., & Berkland, C. J. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.06.029 · Cited by 70
Waithman, J. C., Zanker, D. J., Xiao, K., Oveissi, S., Wylie, B., Ng, R. L. X., Tögel, L., & Chen, W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066136 · Cited by 76
Kokolus, K. M., Spangler, H. M., Povinelli, B. J., Farren, M. R., Lee, K. P., & Repasky, E. A. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00023 · Cited by 67
Dicer-Dependent MicroRNAs Control Maturation, Function, and Maintenance of Langerhans Cells In Vivo
Kuipers, H., Schnorfeil, F. M., Fehling, H.-J., Bartels, H., & Brocker, T. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903912 · Cited by 68
“shown to contribute to this process (4, 14, 15).”
BackgroundOpposing Roles of Dendritic Cell Subsets in Experimental GN
Brähler, S., Zinselmeyer, B. H., Raju, S., Nitschké, M., Suleiman, H. Y., Saunders, B. T., Johnson, M. W., Böhner, A. M. C., Viehmann, S. F., Theisen, D. J., et al. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2017030270 · Cited by 75
Antigen-loaded monocyte administration induces potent therapeutic antitumor T cell responses
Huang, M.-N., Nicholson, L. T., Batich, K. A., Swartz, A. M., Kopin, D., Wellford, S. A., Prabhakar, V. R., Woroniecka, K. I., Nair, S. K., Fecci, P. E., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci128267 · Cited by 72
“To determine if CD8+ cDC mediate the activity of Ag-loaded monocytes in vivo, we adoptively transferred CFSE-labeled OT-I cells into WT or CD8+ cDC-deficient (Batf3-/-) mice (18) and examined splenic OT-I cell proliferation after IV injection of OVA-monocytes.”
BackgroundPerforin-2 is a pore-forming effector of endocytic escape in cross-presenting dendritic cells
Rodríguez-Silvestre, P., Laub, M., Krawczyk, P. A., Davies, A. K., Schessner, J. P., Parveen, R., Tuck, B. J., McEwan, W. A., Borner, G. H. H., & Kozik, P. (2023) · Science · doi:10.1126/science.adg8802 · Cited by 82
Pro-regenerative biomaterials recruit immunoregulatory dendritic cells after traumatic injury
Lokwani, R., Josyula, A., Ngo, T. B., DeStefano, S., Fertil, D., Faust, M. T., Adusei, K. M., Bhuiyan, M., Lin, A., Karkanitsa, M. L., et al. (2023) · Nature Materials · doi:10.1038/s41563-023-01689-9 · Cited by 69
Koltsova, E. K., Hedrick, C. C., & Ley, K. F. (2013) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328363d298 · Cited by 79
Differential Roles of Lung Dendritic Cell Subsets Against Respiratory Virus Infection
Kim, T. H., & Lee, H. K. (2014) · Immune Network · doi:10.4110/in.2014.14.3.128 · Cited by 68
“an efficient CD4 + T cell response to West Nile virus or autoimmune EAE (14,25).”
BackgroundInfluentialFunctional Role of Dendritic Cell Subsets in Cancer Progression and Clinical Implications
Prete, A. D., Sozio, F., Barbazza, I., Salvi, V., Tiberio, L., Laffranchi, M., Gismondi, A., Bosisio, D., Schioppa, T., & Sozzani, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113930 · Cited by 73
Theisen, D. J., Ferris, S. T., Briseño, C. G., Kretzer, N., Iwata, A., Murphy, K. M., & Murphy, T. L. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0138 · Cited by 66
“Batf3 / cDC1 do not mediate fibrosarcoma rejection in vivo Previously, we showed that transplanted immunogenic fibrosarcomas cannot be rejected by Batf3 / mice, but that IL12treated Batf3 / mice reacquire a population of cDC1 cells and can also mount antitumor responses (2, 15).”
BackgroundSelf-citationDesai, P., Jáňová, H., White, J. P., Reynoso, G. V., Hickman, H. D., Baldridge, M. T., Urban, J. F., Stappenbeck, T. S., Thackray, L. B., & Diamond, M. (2021) · Cell · doi:10.1016/j.cell.2021.01.051 · Cited by 66
Price, J. D., & Tarbell, K. V. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00288 · Cited by 83
Harnessing dendritic cells for immunotherapy
Delamarre, L., & Mellman, I. (2011) · Seminars in Immunology · doi:10.1016/j.smim.2011.02.001 · Cited by 75
Perspectives on antigen presenting cells in zebrafish
Lewis, K. L. T., Cid, N. D., & Traver, D. J. (2014) · Developmental & Comparative Immunology · doi:10.1016/j.dci.2014.03.010 · Cited by 81
“…MHC class I receptors, and CD8+ DCs (and related CD103+ DCs in non-lymphoid tissues), which are thought to specialize in cross-presentation, or the presentation of processed external antigen on MHC class I molecules rather than MHC class II molecules (Hildner et al., 2008; Edelson et al., 2010).”
BackgroundSchliehe, C., Redaelli, C., Engelhardt, S., Fehlings, M. G., Mueller, M., van Rooijen, N., Thiry, M., Hildner, K., Weller‡, H., & Groettrup, M. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002084 · Cited by 79
“A mouse model to study the role of CD8 DCs was recently published (38).”
MethodOrigin and functional specializations of DC subsets in the lung
Plantinga, M., Hammad, H., & Lambrecht, B. N. (2010) · European Journal of Immunology · doi:10.1002/eji.201040562 · Cited by 79
Lee, S. H., Carrero, J. A., Uppaluri, R., White, J. M., Archambault, J. M., Lai, K. S., Chan, S. R., Sheehan, K. C. F., Unanue, E. R., & Schreiber, R. D. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300910 · Cited by 66
“DCs are functionally and developmentally related (40).”
Dendritic Cell Maturation Defines Immunological Responsiveness of Tumors to Radiation Therapy
Blair, T. C., Bambina, S., Alice, A. F., Kramer, G. F., Medler, T. R., Baird, J. R., Broz, M. L., Tormoen, G. W., Troesch, V., Crittenden, M. R., et al. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000194 · Cited by 73
Chimeric Antigen Receptor beyond CAR-T Cells
Qin, V. M., D’Souza, C., Neeson, P. J., & Zhu, J. J. (2021) · Cancers · doi:10.3390/cancers13030404 · Cited by 72
“Importantly, cytotoxic CD8+ T cells can be activated by DCs through cross-presentation of TAAs or neoantigens to promote a stronger anti-tumour response [79].”
BackgroundInflammation induces two types of inflammatory dendritic cells in inflamed lymph nodes
Min, J., Yang, D., Kim, S., Haam, K., Yoo, A., Choi, J., Schraml, B. U., Kim, Y. S., Kim, D., & Kang, S. (2018) · Experimental & Molecular Medicine · doi:10.1038/emm.2017.292 · Cited by 75
Kim, S., Kim, S. A., Nam, G., Hong, Y., Kim, G. B., Choi, Y., Lee, S., Cho, Y., Kwon, M., Jeong, C., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001481 · Cited by 74
Type I conventional dendritic cells facilitate immunotherapy in pancreatic cancer
Mahadevan, K. K., Dyevoich, A. M., Chen, Y., Li, B., Sugimoto, H., Sockwell, A. M., McAndrews, K. M., Sthanam, L. K., Wang, H., Shalapour, S., et al. (2024) · Science · doi:10.1126/science.adh4567 · Cited by 78
Wu, X., Satpathy, A. T., Wumesh, K. C., Liu, P., Murphy, T. L., & MURPHY, K. M. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064800 · Cited by 76
“For example, E2-2 is required for development of pDCs [10], Batf3 for CD8 cDCs [11], Irf8 for pDCs and CD8 cDCs [12,13], and the NF-kB family member RelB for CD4 cDCs [5,14,15].”
BackgroundConventional Dendritic Cells Require IRAP-Rab14 Endosomes for Efficient Cross-Presentation
Weimershaus, M., Maschalidi, S., Sepulveda, F. E., Manoury, B., Endert, P. V., & Saveanu, L. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1101504 · Cited by 75
“Dendritic cells (DCs) use cellular pathways collectively referred to as cross-presentation to stimulate CD8+ T cells with peptide Ags derived from internalized, exogenous Ags.”
BackgroundResultInfluentialTrautwein-Weidner, K., Gladiator, A., Kirchner, F. R., Becattini, S., Rülicke, T., Sallusto, F., & LeibundGut-Landmann, S. (2015) · PLOS Pathogens · doi:10.1371/journal.ppat.1005164 · Cited by 65
“Ccr7-/- [18], Batf3-/- [19], Ccr2-/[20] and Flt3l-/- [21] were bred at the Laboratory Animal Service Center (University of Zürich, PLOS Pathogens | DOI:10.1371/journal.ppat.1005164 October 2, 2015 3 / 23 Switzerland).”
BackgroundInfluentialCheng, X., Etalo, D. W., van de Mortel, J. E., Dekkers, E., Nguyen, L., Medema, M. H., & Raaijmakers, J. M. (2017) · Environmental Microbiology · doi:10.1111/1462-2920.13927 · Cited by 76
Type 2 dendritic cells mediate control of cytotoxic T cell resistant tumors
Iwanowycz, S., Ngoi, S. M., Li, Y., Hill, M., Koivisto, C. S., Parrish, M., Guo, B., Li, Z., & Liu, B. (2021) · JCI Insight · doi:10.1172/jci.insight.145885 · Cited by 74
“To investigate the specific contribution of DC1 to the immune environment within PyMT tumors, we implanted PyMT tumor cells into the mammary glands of Batf3 mice, which have significantly impaired DC1 development ((45) and Figure S3A).”
BackgroundLança, T., Ungerbäck, J., Silva, C. D., Joeris, T., Ahmadi, F., Vandamme, J., Svensson, M., Mowat, A. M., Kotarsky, K., Sigvardsson, M., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.06.006 · Cited by 73
Ohara, D., Takeuchi, Y., & Hirota, K. (2024) · Cellular and Molecular Immunology · doi:10.1038/s41423-024-01218-x · Cited by 74
The role of liver sinusoidal cells in local hepatic immune surveillance
Wohlleber, D., & Knolle, P. A. (2016) · Clinical & Translational Immunology · doi:10.1038/cti.2016.74 · Cited by 64
Harnessing the cDC1-NK Cross-Talk in the Tumor Microenvironment to Battle Cancer
Bödder, J., Zahan, T., van Slooten, R., Schreibelt, G., de Vries, I. J. M., & Flórez‐Grau, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.631713 · Cited by 73
Fox, B. A., Sanders, K. L., Rommereim, L. M., Guevara, R. B., & Bzik, D. J. (2016) · PLoS Genetics · doi:10.1371/journal.pgen.1006189 · Cited by 67
“CD11c CD8α dendritic cells have been recognized play an important role in cross presentation of antigens to prime CD8 T cell mediated immunity to tumors [113].”
BackgroundThe role of dendritic cells in tumor microenvironments and their uses as therapeutic targets
Kim, C. W., Kim, K.-D., & Lee, H. K. (2021) · BMB Reports · doi:10.5483/bmbrep.2021.54.1.224 · Cited by 62
“BATF3 deficiency in mice results in CD8 DCs that cannot cross-present to CD8 T cells, leading to lack of tumor rejection (6).”
BackgroundMattsson, J., Schön, K., Ekman, L., Fahlén‐Yrlid, L., Yrlid, U., & Lycke, N. Y. (2014) · Mucosal Immunology · doi:10.1038/mi.2014.111 · Cited by 73
“To further document that CD8aþ DCs were dispensable for the adjuvant effect, we immunized Batf3 / mice with antigen and CT adjuvant, as these mice completely lack the CD8aþ DC subset.(38) We found an intact adjuvant effect with comparable expansion and production of IFN-g by OT-II cells in Baft3 / and WT mice and simi…”
ResultReview of Mouse and Human Dendritic Cell Subsets
Segura, É. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3606-9_1 · Cited by 79
Yi, S., Zhai, J., Niu, R., Zhu, G., Wang, M., Liu, J., Huang, H., Wang, Y., Jing, X., Li, K., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06316-9 · Cited by 71
The role of CMV in glioblastoma and implications for immunotherapeutic strategies
Rahman, M., Dastmalchi, F., Karachi, A., & Mitchell, D. A. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1514921 · Cited by 77
“CMV-specific immune killing of tumor cells results in antigen release and cross priming by dendritic cells (DCs) to other tumorassociated and tumor-specific antigens.(71) These cells thenmagnify the anti-tumor immune response and results in killing of both CMV positive and negative tumor cells (Figure 1c).”
BackgroundAdvantages and limitations of mouse models to deplete dendritic cells
van Blijswijk, J., Schraml, B. U., & Sousa, C. R. E. (2013) · European Journal of Immunology · doi:10.1002/eji.201243022 · Cited by 68
Dammeijer, F. F., Lau, S. P., van Eijck, C. H. J., van der Burg, S. H., & Aerts, J. G. J. V. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.06.011 · Cited by 75
Antigen-presenting dendritic cells in atherosclerosis
Gil‐Pulido, J., & Zernecke, A. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.08.016 · Cited by 73
Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers
Lhuillier, C., Vanpouille-Box, C., Galluzzi, L., Formenti, S. C., & Demaria, S. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.12.007 · Cited by 62
Recent Successes and Future Directions in Immunotherapy of Cutaneous Melanoma
Sadozai, H., Gruber, T., Hunger, R. E., & Schenk, M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01617 · Cited by 67
“In 2008, it was reported that knocking out Batf3 in mice eliminated CD8α+ DC, and consequently it was demonstrated that these mice were incapable of cross-presenting antigen or rejecting highly immunogenic fibrosarcomas (138).”
BackgroundBiology and function of adipose tissue macrophages, dendritic cells and B cells
Ivanov, S., Merlin, J., Lee, M. K. S., Murphy, A. J., & Guinamard, R. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.01.018 · Cited by 73
Role of Dendritic Cells in the Induction of Lymphocyte Tolerance
Osorio, F., Fuentes, C., López, M. N., Salazar‐Onfray, F., & González, F. E. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00535 · Cited by 70
Plasmacytoid Dendritic Cells and Cancer Immunotherapy
Fu, C., Zhou, L., Mi, Q., & Jiang, A. (2022) · Cells · doi:10.3390/cells11020222 · Cited by 65
“cDC1s depend on interferon regulatory factor 8 (IRF8) and basic leucine zipper transcriptional factor ATF-like 3 (Batf3) for their development, and are identified as XCR1hiCD24hiCD26hi CD11chiMHCIIhiCD11bloCD172aloF4/80loCD64loLinlo population in mice and CD141+ (BDCA3+) DCs in human [9,12,13].”
BackgroundTumor-Derived Lysophosphatidic Acid Blunts Protective Type I Interferon Responses in Ovarian Cancer
Chae, C.-S., Sandoval, T. A., Hwang, S., Park, E. S., Giovanelli, P., Awasthi, D., Salvagno, C., Emmanuelli, A., Tan, C., Chaudhary, V., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1181 · Cited by 73
Quintana, E., Fernández, A., Velasco, P., de Andrés, B., Liste, I., Sancho, D., Gaspar, M. L., & Cano, E. (2015) · Glia · doi:10.1002/glia.22889 · Cited by 60
“Deletion of the transcription factor Batf3 has been shown to ablate development of CD8a(1) DCs in the periphery (Hildner et al., 2008).”
BackgroundMethodInfluentialProietto, A., Mittag, D., Roberts, A. W., Sprigg, N. S., & Wu, L. (2012) · Cellular and Molecular Immunology · doi:10.1038/cmi.2012.48 · Cited by 61
Redefining Myeloid Cell Subsets in Murine Spleen
Hey, Y. Y., Tan, J. K. H., & O'Neill, H. C. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00652 · Cited by 74
“Batf3−/− mice contain decreased numbers of CD8+ cDC, but not CD8− cDC, suggesting that Batf3 is essential in the development of CD8+ cDC from pre-cDC (51).”
BackgroundSimonetta, F., Lohmeyer, J. K., Hirai, T., Maas‐Bauer, K., Álvarez, M., Wenokur, A. S., Baker, J. B., Aalipour, A., Ji, X., Haile, S. T., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1329 · Cited by 68
“To test the hypothesis that host CD8 T-cell cross-priming mediates the indirect antitumor effect of allogeneic CAR iNKT cells, we employed as recipients BALB/c BATF3 / mice, in which CD8 T-cell cross-priming is impaired as a result of the absence of BATF3-dependent CD103þ CD8alphaþ dendritic cells (31).”
MethodcDC1 Vaccines Drive Tumor Rejection by Direct Presentation Independently of Host cDC1
Ferris, S. T., Ohara, R. A., Ou, F., Wu, R., Huang, X., Kim, S. K., Chen, J., Liu, T., Schreiber, R. D., Murphy, T. L., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0865 · Cited by 72
Backlund, C. M., Holden, R. L., Moynihan, K. D., Garafola, D., Farquhar, C., Mehta, N. K., Maiorino, L., Pham, S., Iorgulescu, J. B., Reardon, D. A., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2204078119 · Cited by 61
Antigen-presenting cells as specialized drivers of intestinal T cell functions
Kedmi, R., & Littman, D. R. (2024) · Immunity · doi:10.1016/j.immuni.2024.09.011 · Cited by 71
Haynes, N. M., Hawkins, E. D., Li, M., McLaughlin, N. M., Hämmerling, G. J., Schwendener, R. A., Winoto, A., Wensky, A. K., Yagita∥, H., Takeda, K., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903624 · Cited by 61
Pohl, J., Gutweiler, S., Thiebes, S., Volke, J. K., Klein‐Hitpaß, L., Zwanziger, D., Gunzer, M., Jung, S., Agace, W. W., Kurts, C., et al. (2017) · Gut · doi:10.1136/gutjnl-2017-313856 · Cited by 65
Allie, S. R., & Randall, T. D. (2017) · Clinical Science · doi:10.1042/cs20160259 · Cited by 75
Lollies, A., Hartmann, S., Schneider, M., Bracht, T., Weiß, A. L., Arnolds, J., Klein‐Hitpass, L., Sitek, B., Hansmann, M.-L., Küppers, R., et al. (2017) · Leukemia · doi:10.1038/leu.2017.203 · Cited by 69
Cauwels, A., Van Lint, S., Garcin, G., Bultinck, J., Paul, F., Gerlo, S., Van der Heyden, J., Bordat, Y., Catteeuw, D., De Cauwer, L., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1398876 · Cited by 60
“17¡23 As cDC1 require the Batf3 transcription factor for their differentiation, deletion of Batf3 ablates their development.(24) Experiments in cDC1-deficient Batf3¡/¡ mice indicated the absolute requirement for cDC1 for the antitumor efficacy of tumor-targeted AFN (Fig.”
BackgroundOrigin, Localization, and Immunoregulatory Properties of Pulmonary Phagocytes in Allergic Asthma
Hoffmann, F. S., Ender, F., Schmudde, I., Lewkowich, I. P., Köhl, J., König, P., & Laumonnier, Y. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00107 · Cited by 65
“However, the nature of the cytokines (CSF-2 and Flt3L) and of the transcription factors (e.g., Ikaros, PU.1, IRF4, IRF8, and BATF3) involved in human DCs development [reviewed in Ref.”
BackgroundInfluentialMMP2 and TLRs modulate immune responses in the tumor microenvironment
Muniz-Bongers, L. R., McClain, C. B., Saxena, M., Bongers, G., Mérad, M., & Bhardwaj, N. (2021) · JCI Insight · doi:10.1172/jci.insight.144913 · Cited by 68
“To firmly establish a role for DCs, we evaluated the growth of F1, Mmp2-OE, and Mmp2-KO tumors in Batf3–/– mice, which lack the cross-presenting cDC1 (56), including the CD103+ DCs (Figure 6A).”
BackgroundMattiuz, R., Brousse, C., Ambrosini, M., Cancel, J.-C., Bessou, G., Mussard, J., Sanlaville, A., Caux, C., Bendriss‐Vermare, N., Valladeau‐Guilemond, J., et al. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1305 · Cited by 65
An Updated View of the Intracellular Mechanisms Regulating Cross-Presentation
Nair-Gupta, P., & Blander, J. M. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00401 · Cited by 68
Sparber, F., Dolowschiak, T., Mertens, S., Lauener, L., Clausen, B. E., Joller, N., Stoitzner, P., Tussiwand, R., & LeibundGut-Landmann, S. (2018) · PLOS Pathogens · doi:10.1371/journal.ppat.1007069 · Cited by 59
Dendritic Cell Regulation of Graft-Vs.-Host Disease: Immunostimulation and Tolerance
Yu, H., Tian, Y., Wang, Y., Mineishi, S., & Zhang, Y. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00093 · Cited by 65
Klampatsa, A., Leibowitz, M. S., Sun, J., Liousia, M., Arguiri, E., & Albelda, S. Μ. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.07.005 · Cited by 62
“To directly assess the functional importance of cDC1 cells, we utilized commercially available mice in which the BATF3 transcription factor has been deleted, leading to the absence of cDC1 cells.(22) We treated AE17om tumors with 90% mesothelin-expressing cells in WT versus BATF3-deficient mice.”
BackgroundMethodCancer cell CCR2 orchestrates suppression of the adaptive immune response
Fein, M. R., He, X., Almeida, A. S., Bružas, E., Pommier, A., Yan, R., Eberhardt, A., Fearon, D. T., Aelst, L. V., Wilkinson, J. E., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20181551 · Cited by 59
“In contrast, infiltration of CD103+ dendritic cells (DCs) in mice, phenotypically similar to CD141+ DCs in humans (Hildner et al., 2008), has emerged as a mechanism by which tumors may be kept under immune control.”
BackgroundCross‐presenting dendritic cells are required for control of L eishmania major infection
Ashok, D., Schuster, S., Ronet, C., Rosa, M., Mack, V., Lavanchy, C., Marraco, S. A. F., Fasel, N. J., MURPHY, K. M. M., Tacchini‐Cottier, F., et al. (2014) · European Journal of Immunology · doi:10.1002/eji.201344242 · Cited by 59
Hwang, H. S., Cherukula, K., Bang, Y. J., Vijayan, V., Moon, M. J., Thiruppathi, J., Puth, S., Jeong, Y. Y., Park, I., Lee, S. E., et al. (2020) · Cells · doi:10.3390/cells9112432 · Cited by 59
“The Batf3-lineage DCs are known to play important roles in inducing CTLs through antigen cross-presentation [36].”
BackgroundRNA vaccines for cancer: Principles to practice
Guasp, P., Reiche, C., Sethna, Z. M., & Balachandran, V. P. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.05.005 · Cited by 69
Cytosolic cytochrome c represses ferroptosis
Song, X., Zhou, Z., Liu, J., Li, J., Yu, C., Zeh, H. J., Klionsky, D. J., Stockwell, B. R., Wang, J., Kang, R., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.03.014 · Cited by 66
Leukemia-associated activating mutation of Flt3 expands dendritic cells and alters T cell responses
Lau, C. M., Nish, S. A., Yogev, N., Waisman, A., Reiner, S. L., & Reizis, B. (2016) · The Journal of Experimental Medicine · doi:10.1084/jem.20150642 · Cited by 65
“In contrast, Flt3ITD/+ Batf3−/− mice were completely resistant to Lm infection, suggesting that the expanded nc-CD8+ cDCs cannot substitute for the canonical CD8+ cDCs (Fig.”
BackgroundInfluentialCarpentier, S., Vu Manh, T.-P., Chelbi, R., Henri, S., Malissen, B., Haniffa, M., Ginhoux, F., & Dalod, M. (2016) · Journal of Immunological Methods · doi:10.1016/j.jim.2016.02.023 · Cited by 58
“6C) (BATF3, CADM1, GCET2, IDO2, RAB7B, ID2, BTLA, STX3, FAM46C, TAP1, ARHGAP22, RASGPR3) (Galibert et al., 2005; Ginhoux et al., 2009; Grajales-Reyes et al., 2015; Hacker et al., 2003; Haniffa et al., 2012; Hildner et al., 2008; Jackson et al., 2011; Jaiswal et al., 2013; Robbins et al., 2008).”
Chrisikos, T. T., Zhou, Y., Slone, N., Babcock, R. L., Watowich, S. S., & Li, H. S. (2018) · Molecular Immunology · doi:10.1016/j.molimm.2018.01.014 · Cited by 65
“Although it is clear that cDC1s stimulate tumor-reactive CD8+ cytotoxic T cells (Hildner et al., 2008), the mechanisms that enable their selective ability to cross-present antigen are only now being uncovered.”
BackgroundInfluentialTargeting Innate Immunity to Enhance the Efficacy of Radiation Therapy
Dar, T. B., Henson, R. M., & Shiao, S. L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03077 · Cited by 65
State of the art and challenges in sequence based T-cell epitope prediction
Lundegaard, C., Hoof, I., Lund, O., & Nielsen, M. (2010) · Immunome Research · doi:10.1186/1745-7580-6-s2-s3 · Cited by 60
Imaging dendritic cell functions*
Bošnjak, B., Do, K. T. H., Förster, R., & Hammerschmidt, S. I. (2021) · Immunological Reviews · doi:10.1111/imr.13050 · Cited by 60
Gardner, A., Pulido, Á. D. M., Hänggi, K., Bazargan, S., Onimus, A., Kasprzak, A., Conejo-Garcia, J. R., Rejniak, K. A., & Ruffell, B. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003571 · Cited by 62
“…α PD-1 immunotherapy, with increased IFN γ production by T cells able to enhance chemokine and cytokine expression by tumor cDCs. 19 23 It seems likely that CXCL9 will play a similar role in promoting localization of CD8 + T cells and cDC1s during α PD-1 treatment, but this remains to be evaluated.”
Luo, R., Onyshchenko, K., Wang, L., Gaedicke, S., Grosu, A., Firat, E., & Niedermann, G. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1591 · Cited by 63
Alveolar macrophages instruct CD8+ T cell expansion by antigen cross-presentation in lung
Kawasaki, T., Ikegawa, M., Yunoki, K., Otani, H., Ori, D., Ishii, K. J., Kuroda, E., Takamura, S., Kitabatake, M., Ito, T., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111828 · Cited by 63
Zhang, B., Upadhyay, R., Hao, Y., Samanovic, M. I., Herati, R. S., Blair, J. D., Axelrad, J., Mulligan, M. J., Littman, D. R., & Satija, R. (2023) · Nature Immunology · doi:10.1038/s41590-023-01608-9 · Cited by 57
Ao, F., Li, X., Tan, Y. Z., Jiang, Z., Yang, F., Guo, J., Zhu, Q., Chen, Z., Zhou, B., Zhang, K., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.01.048 · Cited by 62
Generation of Immunity against Pathogens via Single-Domain Antibody–Antigen Constructs
Duarte, J. N., Cragnolini, J. J., Swee, L. K., Bilate, A. M. B., Bader, J. M., Ingram, J. R., Rashidfarrokhi, A., Fang, T., Schiepers, A., Hanke, L., et al. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600692 · Cited by 60
CD103+ Dendritic Cell Function Is Altered in the Colons of Patients with Ulcerative Colitis
Matsuno, H., Kayama, H., Nishimura, J., Sekido, Y., Osawa, H., Barman, S., Ogino, T., Takahashi, H., Haraguchi, N., Hata, T., et al. (2017) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000001204 · Cited by 59
The transcription factor Batf3 inhibits the differentiation of regulatory T cells in the periphery
Lee, W., Kim, H. S., Hwang, S. S., & Lee, G. R. (2017) · Experimental & Molecular Medicine · doi:10.1038/emm.2017.157 · Cited by 62
Metadata
- Authors
- Hildner, K., Edelson, B. T., Purtha, W. E., Diamond, M., Matsushita, H., Kohyama, M., Calderon, B., Schraml, B. U., Unanue, E. R., Diamond, M. S., Schreiber, R. D., Murphy, T. L., & Murphy, K. M.
- Affiliations
- Howard Hughes Medical Institute (US)
- Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110, USA.
- Corresponding author
- Murphy, Kenneth M.
- ORCID
- Venue
- Science
- Published
- 2008-11-14
- Volume
- 322
- Issue
- 5904
- Pages
- 1097-1100
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC2756611
- OpenAlex
- W2046505430
- Cited by
- 2,081
- References
- 29
- Citations by year
- 2026: 117 · 2025: 150 · 2024: 142 · 2023: 129 · 2022: 161 · 2021: 167 · 2020: 182 · 2019: 129 · 2018: 109 · 2017: 133 · 2016: 115 · 2015: 105 · 2014: 92 · 2013: 89 · 2012: 90
- FWCI
- 23.50
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Howard Hughes Medical Institute
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Keywords
- Batf3, CD8α+ dendritic cells, cross-presentation, West Nile virus, tumor rejection, dendritic cell development, transcription factors, antitumor immunity
- MeSH terms
- Animals, Antibodies, Viral, Cytotoxicity, Immunologic, Dendritic Cells, Female, Fibrosarcoma, Lymphocyte Activation, Male, Mice, Inbred C57BL, Repressor Proteins, Spleen, T-Lymphocytes, Cytotoxic, West Nile Fever, West Nile virus, CD4-Positive T-Lymphocytes, CD8 Antigens, Adoptive Transfer, Cross-Priming, Basic-Leucine Zipper Transcription Factors, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.